40321-86-6

40321-86-6 structure

Name: niclosamide sodium salt
Chemical Name: niclosamide sodium salt
CAS Number: 40321-86-6
Molecular Formula: C₁₃H₇Cl₂N₂NaO₄
Molecular Weight: 349.10100
Catalog: Signaling Pathways JAK/STAT Signaling STAT
Create Date: 2018-04-18 08:57:37
Modify Date: 2024-01-11 23:47:58
Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].

Name	niclosamide sodium salt

Description	Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].
Related Catalog	Signaling Pathways >> Stem Cell/Wnt >> STAT Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> JAK/STAT Signaling >> STAT
In Vitro	Niclosamide sodium (0.6 nM-46 µM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells[3]. Niclosamide sodium (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells[4]. Niclosamide sodium (10 μM) treatment inhibits virus replication in Vero E6 cells[5]. Cell Viability Assay[3] Cell Line: BD140A, SW-13 and NCI-H295R cells Concentration: 0.6 nM-46 µM Incubation Time: Result: Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50 of 0.12 µM, 0.15 µM, and 0.53 µM in BD140A, SW-13, and NCI-H295R, respectively. Cell Viability Assay[4] Cell Line: Hela cells Concentration: 0.05-5 μM Incubation Time: 24 hours Result: Inhibited STAT3-mediated luciferase reporter activity with an IC50 of 0.25 μM. Western Blot Analysis[5] Cell Line: Vero E6 cells Concentration: 10 μM Incubation Time: 2 days Result: Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.
In Vivo	Niclosamide sodium (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo[3]. Animal Model: Nu+/Nu+ mice injected with NCI-H295R cells[3] Dosage: 100 mg/kg, 200 mg/kg Administration: Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks Result: Showed a 60%-80% inhibition in tumor growth, as compared to the control group.
References	[1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95. [2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96. [3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66. [4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9. [5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.

Molecular Formula	C₁₃H₇Cl₂N₂NaO₄
Molecular Weight	349.10100
Exact Mass	347.96800
PSA	97.98000
LogP	4.89390

40321-86-6	9085-26-1
71119-23-8	54524-32-2
62696-99-5	23255-99-4
127373-66-4	87713-30-2
68244-58-6	18763-65-0
1158522-08-7	940364-43-2
161618-30-0	134104-43-1
131615-57-1	6906-52-1
71318-22-4	930439-75-1
82736-23-0	1018584-77-4